Mucolipidosis IV (MLIV) is a severe lysosomal storage disorder, which results from loss of the TRPML1 channel. MLIV causes multiple impairments in young children, including severe motor deficits. Currently, there is no effective treatment. Using a Drosophila MLIV model, we showed previously that introduction of trpml þ in phagocytic glia rescued the locomotor deficit by removing early dying neurons, thereby preventing amplification of neuronal death from cytotoxicity. Because microglia, which are phagocytic cells in the mammalian brain, are bone marrow derived, and cross the blood-brain barrier, we used a mouse MLIV model to test the efficacy of bone marrow transplantation (BMT). We found that BMT suppressed the reduced myelination and the increased caspase-3 activity due to loss of TRPML1. Using a rotarod test, we demonstrated that early BMT greatly delayed the motor impairment in the mutant mice. These data offer the possibility that BMT might provide the first therapy for MLIV.
Introduction
Mucolipidosis type IV (MLIV) is an early-childhood-onset neurodegenerative disorder which results in profound neurological defects, including severe motor deficits (1) . This lysosomal storage disorder (LSD) is caused by loss-of-function mutations in the MCOLN1 gene, which encodes the late endosomal/lysosomal TRPML1 cation channel (2) (3) (4) . TRPML1 functions in the efflux of Ca 2þ , Na þ and some heavy metal cations from the lysosomal lumen to the cytosol, and helps to regulate lysosomal pH and ion homeostasis (5) (6) (7) (8) . Loss of TRPML1 expression in mice results in multiple deficits, including a progressive loss of hindlimb motor activity (9) . The Mcoln1 À/À animals display a measurable loss in strength in 2-3 months-old mutants, but the motor deficits are not clearly visible until 6.5 months of age (9) . We previously developed a Drosophila MLIV model, and showed that mutation of fly trpml also caused neurodegeneration and motor problems (6) . Introduction of a trpml þ transgene specifically in neurons fully rescued these impairments. As one of our negative controls, we expressed trpml þ exclusively in glia.
Unexpectedly, this also suppressed the rapid neurodegeneration and locomotor deficits. The glial-specific rescue results because phagocytic glia in the brain remove early dying neurons before they progress to late dying neurons and release cytotoxic agents that accelerates further neuronal death (6) . On the basis of this finding, we proposed that restoring wild-type phagocytic glial activity in the mammalian brain would similarly suppress the rapid expansion of neurodegeneration (6) . In further support of this concept, mammalian TRPML1 is also required in myelinating glia of the brain (10, 11) . Microglia are the professional phagocytes in the mammalian central nervous system and are derived from bone marrow stem cells. Therefore, we set out to restore phagocytic glial activity in the brain by introducing wildtype microglia through bone marrow transplantation (BMT) (6) . BMT has been investigated as part of an enzyme replacement regime in several LSD mouse models (12) (13) (14) (15) (16) (17) . However, BMT had not been tested for MLIV, since unlike other LSDs, MLIV results from a mutation in the gene encoding the TRPML1 channel, rather than an enzyme. Here the concept for BMT was different-to replace impaired microglia needed for phagocytosis of dying neurons, rather than to supply a missing enzyme to the neurons. In this study, we demonstrate that BMT performed on young Mcoln1 À/À mice suppresses defects in myelination, and accumulation of apoptotic neurons. Most strikingly, BMT greatly delays the onset of motor deficits, which we show are evident in the untreated mutants by 6 weeks of age. These findings support the proposal that BMT might represent a therapy to delay the motor deficits associated with MLIV.
Results
Early onset and progressive motor delay in Mcoln1 
Rescue of defects in motor neuron myelin thickness
Progressive hindlimb paralysis is a pronounced phenotypic indicator of neurodegeneration in the MLIV mouse model (9) . These findings suggest that the effects on locomotor activity occur at least in part through impairments in the most distal regions of the nervous system. Neurological input into muscles of the hindlimb is transmitted through axons in the sciatic nerve.
To analyze the effect that the loss of TRPML1 function has on peripheral nerves, we examined axons of the sciatic nerve, which are critical for normal hindlimb motor activity. The sciatic nerve is composed of myelinated and nonmyelinated axons. Myelin-expressing Schwann cells wrap around the outer surface of myelinated axons to form a thick outer layer. The thickness of the myelin layer is important to the conductance and signal transmission within these axons. Using electron microscopy, we measured the myelin thickness and calculated the g-ratio of myelinated axons. Control mice had an average g-ratio of 0.59 and only 1.6% of all axons had a g-ratio >0.7 ( Fig. 2A-C) . Consistent with previous reports (11, 18) , we found that Mcoln1 À/À mice had a large increase in the percentage of thinly myelinated axons with a g-ratio >0.7 (12.6%) ( Fig. 2D-F) . Strikingly, BMT treatment fully reversed the accumulation of these thinly myelinated axons in Mcoln1 À/À animals, as only 1.3% displayed a g-ratio >0.7 ( Fig. 2G-I ). In addition to thinning myelin, the sciatic nerves of 15-week-old Mcoln1 À/À mice displayed increased numbers of damaged axons in which the axons were separating from the myelin sheath and showed buckling and splitting of the myelin (Fig. 3A , B and D). Cerebellar neurons from 15-week-old mutant mice also exhibited dramatic reductions in the intensity of staining with NeuN-an antibody targeting a neuronal-specific RNA splicing factor, which decreases in intensity in degenerating neurons ( Fig. 4) (19, 20) . However, there were no apparent reductions in axon numbers in the sciatic nerve ( 
Reduction in accumulation of apoptotic cells
To test whether the BMT reduced apoptotic cell accumulation, we stained sciatic nerve sections with antibodies against activated caspase-3, which marks apoptotic cells (21) . In sections from control animals, we detected relatively little staining ( During cell clearance, phagocytic macrophage/microglia are activated and infiltrate tissue to move toward and engulf apoptotic cells. We used anti-Iba1 staining to detect macrophage/ microglia activity in the sciatic nerve. Consistent with the increased caspase-3 activity, Mcoln1
À/À mice exhibited elevated macrophage/microglia activity (Fig. 5E , F and H). We found that the BMT treated mice also had elevated anti-Iba1 staining ( Fig.  5G and H) . Because the treated mice were Mcoln1 À/À mutants, there was still an increase in primary neuronal cell death. As a consequence, the macrophages/microglia were active in order to remove the dying cells.
Delay in motor deficits in Mcoln1
À/À mice by BMT A key question was whether BMT would suppress the decline in motor function. If successful, the treatment would delay the loss in motor function since the decrease in function due to the bystander effect would be reduced or eliminated. However, this treatment would not necessarily permanently rescue the impairment since the primary cell death would still take place. To assess the efficacy of the BMT, we used the rotarod, and tested animals at 6, 15 and 32 weeks of age. As described above, untreated control animals displayed constant run times over (Fig. 6A) . When we performed the BMT on 6-week-old mutant mice, there was no improvement (Fig. 6B) . Remarkably, we found that application of BMT treatment to 8-10 day old Mcoln1 À/À animals resulted in a profound benefit. 6
and 15-week-old Mcoln1 À/À animals performed similar to untreated control mice, or to control animals that underwent BMT ( Fig. 6C and D) . Even at 32 weeks of age, the treated Mcoln1 À/À mice exhibited run times indistinguishable from treated controls ( Fig. 6C and D) . However, at 32 weeks of age, the control mice that were exposed to the BMT failed to maintain the same rotarod performance as the untreated control animals. We reduced the irradiation from 3 Gy to 1 Gy and this change eliminated the adverse effect to 32-week-old controls, but did not further improve the performance of the treated 32-week-old Mcoln1 À/À mice ( Fig. 6E and F ).
Discussion
Currently, there is no effective treatment for MLIV. To develop a therapeutic concept for this devastating disorder, we took advantage of the finding that the neurodegeneration and motor problems in a fly MLIV model were reduced by expressing the wild-type TRPML1 homolog specifically in glia (6) . In flies, the suppression resulted from removal of early apoptotic neurons before they progressed to late apoptotic neurons and released cytotoxic agents that accelerated cell death due to a bystander effect (6) . Because microglia are phagocytic and bone marrow derived, we used the mouse MLIV model (9) to test the effectiveness of BMT. The first challenge to testing the idea that BMT might provide a treatment was to ascertain whether TRPML1-deficient mice displayed early onset motor problems, as is the case in MLIV patients.
Mcoln1
À/À mice exhibit changes in gait (9).
However, this phenotype is not clearly detectable until $6.5 months of age. We found that the rotarod provided a sensitive assay, which revealed deficits in motor function in 6-week-old Mcoln1 À/À mice. The sensitivity of this assay allowed us to distinguish and quantify motor deficits in mutant animals much earlier than before, and the impairments are consistent with the early onset motor defects in MLIV patients (22) . We found that BMT greatly delayed the onset of the motor problems, but only if the BMT was performed on young, 8-10-dold mutant animals. When the BMT was performed at 6 weeks of age, there was no amelioration of rotarod performance. This suggests that if BMT were to be performed on MLIV patients, it would need to be conducted on young patients. This may be feasible, since most MLIV patients are diagnosed very early at 1-2 years of age, when the individuals begin to show early deficits in achieving developmental milestones (1) .
The BMT appeared to fully suppress the motor deficits of 6-and 15-week-old Mcoln1 À/À animals. However, by 32 weeks, the treated mutants were no longer performing on the rotarods as well as control animals. Nevertheless, the 32-week-old treated Mcoln1 À/À mice displayed run times similar to the untreated mutant at 6 weeks of age. The eventual reduction in performance in older animals was not surprising, since the primary deficit in neurons remained. We suggest that the BMT suppressed the motor impairment due to removal of early apoptotic neurons by microglia, thereby diminishing a bystander effect. Consistent with this conclusion, we found that BMT decreased the accumulation of apoptotic neurons, as indicated by caspase-3 staining. We also suggest that BMT restored phagocytosis of myelin by the macrophages/microglia. Myelin removal is an important aspect of nerve repair in the peripheral nervous system, as it is critical for new axons to reinnervate nerves (23) . While the improvement in motor function was dramatic, not every aspect of the Mcoln1 À/À phenotype was ameliorated, as we did not detect reduced retinal degeneration, as indicated by the thinner outer nuclear layer (Supplementary Material, Fig. S1 ).
In conclusion, this study provides the first potential therapeutic approach to delay the motor deficits in MLIV patients, and also the first possible therapy for a "TRPopathy." An additional step will be to identify strategies to reduce the primary cell death of the neurons. Along these lines is a recent study in which small molecules ameliorate the effects of defective TRPML1 in a cell line isolated from patients (24) . Loss of Drosophila TRPML and mammalian TRPML1 function reduces TORC1 activity and causes incomplete autophagy (6, (25) (26) (27) (28) (29) (30) (31) , effects that are reduced in flies by amino acid supplementation (26) . Thus, a combination of BMT along with a protein-rich diet and small molecule therapy could potentially provide even greater suppression of the MLIV deficits.
Materials and Methods

Mouse lines and genotyping
The Mcoln À/À mouse line were generated previously (9 heat kill the proteinase K activity, and then placed them on ice. The lysates were later used as the sources of the DNA templates for the PCR reactions. PCR was performed using Taq DNA polymerase (Apex). B6-Ly5.2/Cr (NCI-Frederick) mice were used as bone marrow donor animals. All breeding and other mouse procedures were approved by the Johns Hopkins University School of Medicine Animal Care and Use Committee.
Chemicals
DirectPCR (Viagen), proteinase K (Roche), RBC Lysis Buffer (Affymetrix eBioscience), VECTASHIELD mounting medium (Vector Laboratories) and Hoechst 33342 (Thermo Fisher) were obtained from the indicated sources. We purchased phosphatebuffered saline and fetal bovine serum from Invitrogen. The following chemicals were purchased from Sigma-Aldrich: sucrose, normal goat serum, Triton X-100, sucrose, Permount and ethanol. The following chemicals were purchased from Electron Microscopy Sciences: paraformaldehyde, OCT freezing medium, sodium cacodylate, osmium tetroxide, glutaraldehyde, potassium ferrocyanide, propylene oxide, methylene blue, ERL 4206, DER 736, NSA and DMAE.
Rotarod performance test
We performed rotarod testing using a Rotamex 5 (Columbus Instruments, OH). The rotating rod was suspended $35 cm above the base of the apparatus. The rotation speed, which was monitored by a computer, started at 5 RPMs and increased 1 RPM every 5 s. Once the mouse fell off of the rod, the test was terminated and the run time was recorded. Weekly testing of the animals was initiated when the animals reached 6 weeks of age, and terminated at 32 weeks of age.
Hematopoietic stem cell transplantation
We administered BMT either when the mice were 8-10 days old or 6 weeks old. To deplete endogenous hematopoietic stem cells, we irradiated the animals with a 137
Cs source at the following doses: 8-10 days old, 1 or 3 Gy; 6 weeks old, 9.7 Gy. Donor bone marrow cells were harvested from the femurs and tibias of 6-10-week old C57BL/6-Ly5.2/Cr (NCI-Frederick) congenic mice. The cells were resuspended in phosphate-buffered saline (PBS) with 2.5% fetal bovine serum (FBS) and filtered through a 70 lm cell strainer. Recipient mice were injected with donor bone marrow cells 4-8 h post-irradiation. Six-week-old mice were injected in the tail vein with 1 Â 10 6 cells (in 250 ll) and 8 -10-day old mice were injected with 1 Â 10 6 cells in 250 ll in the retroorbital sinus.
Examining bone marrow engraftment
To examine the extent of donor bone marrow engraftment in transplanted mice, we collected $100 ll blood using a 5 mm lancet to puncture the submandibular vein. To remove red blood cells (RBCs), we added 900 ll RBC Lysis Buffer and transferred The error bars indicate S.E.M.s and the asterisks indicate statistically significant differences (P < 0.05).
the mixture to a 1.5 ml microfuge tube. The mixture was incubated at room temperature for 5 min and centrifuged at 400 Â g for 1 min. The supernatant was removed and the remaining hematopoietic stem cells were resuspended in 100 ll of PBS 
Immunohistochemical staining of brains for donorderived cells
Mice were euthanized and transcardially perfused with PBS followed by 4% paraformaldehyde (PFA) in PBS. Brains were dissected from the skull and incubated in PFA overnight at 4 C, followed by three washes with PBS. The brains were incubated overnight in 30% sucrose in PBS, and embedded in OCT freezing medium. We prepared 20 lm sections, which we blocked and permeabilized with blocking buffer (5% normal goat serum and 0.3% Triton X-100 in PBS) for 1 h at room temperature. We incubated the sections with anti-CD45.1 antibody (eBiosciences) in blocking buffer overnight at 4 C. Sections were washed 5Â with PBS and incubated for 1 h at room temperature with Alexafluor 568 anti-rat antibodies (Invitrogen) at a 1:1000 dilution in blocking buffer. The slides were washed 5Â with PBS and mounted in VECTASHIELD mounting medium. Brains were imaged using a Zeiss LSM 700 confocal microscope at 40Â magnification.
Electron microscopic analysis of myelination thickness in sciatic nerves
To assess the thickness of the myelin layer in the sciatic nerve, we transcardially perfused mice with PBS followed by 4% PFA in PBS. We dissected the sciatic nerve, fixed the tissue in 2% PFA containing 2% glutaraldehyde plus 2.5% sucrose in 0.1 M sodium cacodylate pH 7.4 for 2 h, and washed the tissue three times in 0.1 M sodium cacodylate, 2.5% sucrose and 5 mM CaCl 2 . The tissue was stained in freshly made reduced osmium tetroxide (OsO 4 ) staining solution. The staining solution was made in two parts: (a) 80 mg of potassium ferrocyanide in 4 ml of 0.1 M sodium cacodylate pH 7.4 and 2.5% sucrose, and (b) 2 ml of 4% OsO 4 in 2 ml of 0.2 M sodium cacodylate pH 7.4 plus 2.5% sucrose. The tissue was resuspended in OsO 4 staining solution and incubated on ice for 2 h in the dark. We then washed the tissue three times for 10 min with H 2 O and incubated the samples in 2% uranyl acetate for 30 min. We dehydrated the tissue with a series of 5 min washes in increasing concentrations of ethanol: 50%, 70% and 90%. We then washed the tissue three times for 5 min each with 100% ethanol and twice with propylene oxide for 5 min. The tissue was resuspended in a 1:1 mixture of propylene oxide and low viscosity Spurr's embedding resin (5 ml ERL 4206, 3 ml DER 736, 13 ml NSA and 0.2 ml DMAE) for 1 h at room temperature. The mixture was replaced with 100% Spurr's embedding resin and incubated overnight at room temperature. Tissues were transferred to fresh 100% Spurr's embedding resin and set in a mold for polymerization. The samples were incubated at 60 C overnight to cure the resin. Sections of 50-70 nm were collected and imaged on a Phillips 120 transmission electron microscope. Images were analyzed using ImageJ software and the GRatio plugin (http://gratio.efil.de/) to calculate the myelin g-ratio and axon diameter. The asterisks indicate statistically significant differences (P < 0.05).
Light microscopic analysis of damaged axons in the sciatic nerve
We used sciatic nerves that were stained and embedded in Spurr's resin as described above. Cross-sections of 0.5 lm were dried onto a glass slide. The samples were stained with 1% methylene blue for 30 s, rinsed thoroughly with H 2 0, and allowed to dry completely. We mounted a coverslip using Permount mounting media, allowed the mounting media to cure at room temperature overnight and captured images at 160Â magnification with a light microscope (Zeiss Axiovert). Captured images were analyzed using image J to count the total number of normal and damaged myelinated axons within 100 lm 2 areas. We identified damaged axons by looking for buckling and splitting in the myelin, and axon separation from the myelin sheath.
Immunohistochemical staining of sciatic nerves and the cerebellum
Mice were euthanized and transcardially perfused with PBS followed by 4% paraformaldehyde in PBS. After the dissections, the tissues were incubated in paraformaldehyde overnight at 4 C, washed three times with PBS, incubated overnight in 30% sucrose in PBS, and embedded in OCT freezing medium. We prepared 20 lm sections, which we blocked and permeabilized with blocking buffer (5% normal goat serum and 0.3% Triton X-100 in PBS) for 1 h at RT. We incubated the sections of sciatic nerves with the following primary antibodies in blocking buffer overnight at 4 C: rabbit anti-caspase-3, 1:200 dilution (Cell Signaling)
or rabbit anti-Iba1, 1:100 dilution (Wako). The sections were washed five times with PBS and incubated for 1 h at RT with secondary antibodies (Alexafluor 647 anti-rabbit, 1:1000 dilution, Invitrogen) in blocking buffer. The slides were washed five times with PBS and mounted in VECTASHIELD mounting medium. For mouse cerebellar sections we incubated the samples overnight at 4 C with primary antibodies (mouse anti-NeuN, 1:1000 dilution, Millipore) in blocking buffer. The sections were washed five times with PBS and incubated for 1 h at RT with secondary antibodies (Alexafluor 633 anti-mouse, 1:1000 dilution, Invitrogen) in blocking buffer. The slides were washed five times with PBS and mounted in VECTASHIELD mounting medium. Images were captured on a Zeiss LSM 780 confocal microscope. We measured fluorescence with the Image J software. Relative fluorescence ¼ (fluorescence of the antibody stained sciatic nerve cross section)À(the image average background fluorescence of the sciatic nerve). The average background was determined by sampling the background at three positions in the image, calculating the average and multiplying the average by the area of the sciatic nerve.
Statistical analyses
We used unpaired Student t-tests with two-tail analyses for the rotarod and sciatic nerves. To analyze the anti-caspase-3 or antiIba1staining of sciatic nerves and NeuN staining of cerebellar neurons, we used a one-way ANOVA test with the BonferroniHolm post hoc test. Error bars indicate S.E.M.s and the asterisks indicate statistically significant differences (P < 0.05).
Supplementary Material
Supplementary Material is available at HMG online.
